Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.46B
Close$
$112.47
54.8% upside
Current Fair Value
54.8% upsideUndervalued by 54.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.46 Billion |
|---|---|
| Enterprise Value | $7.38 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.36 |
| Outstanding Shares | 104,435,000 |
Return
| Return on Equity | 7.38% |
|---|---|
| Return on Assets | 5.77% |
| Return on Invested Capital | 0.33% |
Valuation & Multiples
| P/E Ratio | 151.5 |
|---|---|
| PEG | -59.69 |
| Price to Sales | 10.38 |
| Price to Book Ratio | 12.11 |
| Enterprise Value to Revenue | 9.59 |
| Enterprise Value to EBIT | 3312.13 |
| Enterprise Value to Net Income | 156 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$185.83 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$219.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0773▼ 134.28% |
|---|---|
| Total Calls | 1,027,301▼ 29.26% |
| Total Puts | 2,134,000▼ 57.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.26%▲ 2.30% |
|---|---|
| Total Invested | $3.19B▲ 19.45% |
| Investors Holding | 365▼ 53.00% |
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...